First Bancorp Inc ME Invests $500,000 in IDEXX Laboratories, Inc. $IDXX

First Bancorp Inc ME bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 950 shares of the company’s stock, valued at approximately $500,000.

Other large investors have also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $25,000. SHP Wealth Management acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Elevation Wealth Partners LLC boosted its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the period. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $26,000. Finally, WealthCollab LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IDXX shares. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group upped their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Citigroup increased their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Stock Performance

IDXX opened at $550.01 on Wednesday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $559.34 and its 200-day moving average is $575.26. The stock has a market cap of $43.33 billion, a PE ratio of 38.68, a price-to-earnings-growth ratio of 2.99 and a beta of 1.54. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.